(Reuters) — Pfizer Inc. and its German partner BioNTech are preparing for a 2024 trial with Moderna Inc. at London’s High Court in competing patent cases over their rival COVID-19 vaccines.
The case reached London’s High Court for the first time for a preliminary hearing on Thursday, ahead of a trial due to take place in April 2024.
Pfizer and BioNTech sued Moderna in London in September to revoke two of Moderna’s patents relating to its messenger RNA (mRNA) vaccine.
Moderna filed its own lawsuit that month over Pfizer and BioNTech’s Comirnaty vaccine, seeking damages for alleged infringement of its patents.
Pfizer, BioNTech and Moderna are also engaged in litigation in Germany, the Netherlands and the United States.
Moderna̵7;s German and US lawsuits, which were filed on the same day in August, both seek financial damages. Pfizer and BioNTech fight back in the US.
All three companies are also involved in US patent disputes with other companies over the vaccines.